The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice
Molecules · 2023
DOI: 10.3390/molecules28062624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Timur Zanikov und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 3M4, Canada. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Encephalitis. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mitacs, GoodCap Pharmaceuticals.
Abstract (Originalsprache)
Inflammation is an organism’s biological defense mechanism. Acute and chronic inflammation of the body triggers the production of pro- and anti-inflammatory pathways that can affect the content of cytokines in the brain and thus cause brain inflammation. Disorders such as depression and posttraumatic stress disorder (PTSD) are often associated with elevated inflammation. Recently, positive and promising clinical results of psilocybin for the treatment of depression and PTSD were reported. Thus, we decided to test whether psilocybin alone or in combination with eugenol, an anti-inflammatory and antioxidant agent, would prevent the increase in or decrease the content of cytokines in the brain of C57BL/6J mice injected with lipopolysaccharides (LPS). Two experiments were performed, one with pre-treatment of mice through gavage with psilocybin (0.88 mg/kg), eugenol (17.6 mg/kg), or combinations of psilocybin and eugenol (1:10, 1:20, or 1:50), followed by intraperitoneal injection of LPS, and the second, post-treatment, with initial injection with LPS, followed by treatment with psilocybin, eugenol, or their combination. Brain tissues were collected, and cytokines were analyzed by qRT-PCR, Western blot, and ELISA. Data were analyzed with a one-way ANOVA followed by Tukey’s post hoc test or with multiple unpaired t-tests. LPS upregulated mRNA expression of COX-2, TNF-α, IL-1β, and IL-6. All pre-treatments decreased the expression of COX-2 and TNF-α, with psilocybin alone and in 1:50 combination, with eugenol being the most effective. In the post-treatment, all combinations of psilocybin and eugenol were effective in reducing inflammation, with the 1:50 ratio displaying the most prominent results in reducing the mRNA content of tested cytokines. Western blot analysis confirmed the effect on COX-2 and IL-1β proteins. Finally, the ELISA showed that post-treatment with psilocybin + eugenol (1:50) demonstrated the best results, decreasing the expression of multiple markers including IL-6 and IL-8. This demonstrates the anti-inflammatory effects of a combination of psilocybin and eugenol in the brain of animals with systemically induced inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 3M4, Canada.
- Institute for Medical Nutrition Science, Universität zu Lübeck, 23562 Lübeck, Germany.
- School of Biosciences and Technology, Vellore Institute of Technology, Vellore 632014, India.
- Department of Medicine, Medical Sciences, and Nutrition, University of Aberdeen, King's College, Aberdeen AB24 3FX, UK.
- GoodCap Pharmaceuticals, 520 3rd Avenue SW, Suite 1900, Calgary, AB T2P 0R3, Canada.
- Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
ORCID-Profile: Marta Gerasymchuk, Gregory Ian Robinson, Alyssa Groves, Mackenzie Cameron, Igor Kovalchuk
Förderung
- Mitacs
- GoodCap Pharmaceuticals
Zitieren
APA
Zanikov, T., Gerasymchuk, M., Ghasemi Gojani, E., Robinson, G. I., Asghari, S., Groves, A., Haselhorst, L., Nandakumar, S., Stahl, C., Cameron, M., Li, D., Rodriguez-Juarez, R., Snelling, A., Hudson, D., Fiselier, A., Kovalchuk, O., & Kovalchuk, I. (2023). The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice. Molecules. https://doi.org/10.3390/molecules28062624
Vancouver
Zanikov T, Gerasymchuk M, Ghasemi Gojani E, Robinson GI, Asghari S, Groves A, et al. The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice. Molecules. 2023. doi:10.3390/molecules28062624
BibTeX
@article{Zanikov2023,
author = {Zanikov, Timur and Gerasymchuk, Marta and Ghasemi Gojani, Esmaeel and Robinson, Gregory Ian and Asghari, Shima and Groves, Alyssa and Haselhorst, Lucie and Nandakumar, Sanjana and Stahl, Cora and Cameron, Mackenzie and Li, Dongping and Rodriguez-Juarez, Rocio and Snelling, Alexandra and Hudson, Darryl and Fiselier, Anna and Kovalchuk, Olga and Kovalchuk, Igor},
title = {The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28062624}
}
EUVIMED